Omnes and Merieux Equity Partners led a €20m Series A round in SeqOne Genomics, a biotechnology company, with participation from Software Club, IRDI and Elaia. "We are extremely happy to have closed this round with leading investors who bring extensive experience in deep-tech, healthcare and biotherapy and who share our vision of building SeqOne into a global leader in personalized medicine. The funding will give us the resources we need to enhance and commercialize our solution to make genomic analysis more accessible and affordable so that each patient can benefit from personalized medicine recommendations," Nicolas Philippe, SeqOne Genomics Co-Founder and CEO.